Overview GLP3-R is the catalog designation for retatrutide (LY3437943), a synthetic peptide characterized in the peer-reviewed literature as a single-molecule agonist at three receptors: GIP, GLP-1, and glucagon.[1] Coskun and colleagues published the discovery-to-proof-of-concept characterization in Cell Metabolism, and Urva et al. reported the first multiple-ascending-dose clinical pharmacology study in The Lancet.[1][2] What distinguishes this compound within the incretin literature is the th

How does GLP3-R work? What is its mechanism of action?

Reported Mechanism 1. Triple Receptor Engagement Retatrutide is described as engaging three class-B G-protein-coupled receptors with a single peptide sequence: the GIP receptor, the GLP-1 receptor, and the glucagon receptor.[1] This distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism, and it is the structural feature that defines the compound's research role.[8] 2. Incretin-Axis Signalling GLP-1 and GIP receptor agonism act on the incretin axis, where insulinotropic act

What are the research applications of GLP3-R?

Research Applications Published investigations of retatrutide fall into the following areas. All studies listed used the pharmaceutical formulation. Receptor pharmacology and discovery characterization — Coskun et al. reported the discovery-to-proof-of-concept work defining triple GIP/GLP-1/glucagon agonism.[1] Clinical pharmacology and dose-ranging — Urva et al. published a phase 1b multiple-ascending-dose trial in people with type 2 diabetes.[2] Obesity research — Jastreboff et al. reported a

What does the research summary say about GLP3-R?

Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al. (2022)Discovery / proof of conceptCharacterization of LY3437943 as a triple glucagon, GIP, and GLP-1 receptor agonist[1] Urva et al. (2022)Phase 1b multiple-ascending doseClinical pharmacology in people with type 2 diabetes[2] Jastreboff et al. (2023)Phase 2 (obesity)Triple-hormone-receptor agonist evaluated in adults with obesity[3] Rosenstock et al. (2023)Phase 2 (type 2 diabetes)Placebo- and active-controlled pa

How should GLP3-R be stored?

Store lyophilized at -20°C for long-term storage, or 2-8°C short-term. After reconstitution with bacteriostatic water, store refrigerated (2-8°C) and avoid repeated freeze-thaw cycles.

How to Store GLP3-R — Storage & Handling Guide

Lyophilized Peptide Storage

Store lyophilized vials at -20°C for long-term stability, protected from light and moisture. Short-term storage at 2°C to 8°C is acceptable. The powder is hygroscopic — keep tightly sealed.

Reconstitution

Reconstitute with bacteriostatic water, adding the diluent slowly down the inside wall of the vial and swirling gently — do not shake. The reconstituted solution should appear clear and colorless.

After Reconstitution

Store the reconstituted solution refrigerated at 2°C to 8°C. Aliquot to avoid repeated freeze-thaw cycles, which degrade peptide integrity.

Handling Precautions

Inspect the reconstituted solution before use. Do not use if it appears cloudy, discolored, or contains particulate matter. Each vial is accompanied by a Certificate of Analysis (COA) detailing purity verification via RP-HPLC and Mass Spectrometry.

Lyophilized Peptide Storage

Reconstitution

After Reconstitution

Store the reconstituted solution refrigerated at 2°C to 8°C. Aliquot to avoid repeated freeze-thaw cycles, which degrade peptide integrity.

Storing GLP3-R: Best Practices

Lyophilized Peptide Storage

Reconstitution

After Reconstitution

Handling Precautions

Referencias

Perguntas de Pesquisa Relacionadas

Related research

Storing GLP3-R: Best Practices

Lyophilized Peptide Storage

Reconstitution

After Reconstitution

Handling Precautions

Referencias

Perguntas de Pesquisa Relacionadas

Related research